Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | PNMT | P11086 | 7/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250910 | 0.82 | MAPT (0.50) | TBXA2R | |
| SCHEMBL9716393 | 0.77 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6252014 | 0.76 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CDRD3 | |
| SCHEMBL6253652 | 0.76 | GRIN2B (0.44) | GRIN2BDRD3 | |
| Hydrochloric Acid SCHEMBL9716433 | 0.76 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1951839 | 0.75 | PNMT (0.41) | GRIN2BPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL8186614 | 0.75 | GRIN2B (0.73) | GRIN2BPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6558753 | 0.75 | CA12 (0.61) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL12355694 | 0.75 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL31683946 | 0.74 | PNMT (0.64) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949575-B2 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | PFIZER INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1284958-B1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOIDANE DERIVATIVES | WARNER LAMBERT CO (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20030220382-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | BARTA NANCY SUE (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1284958-A1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOIDANE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001083425-A1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOINDANE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220382-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | APP, APBA1, PSEN1 | GRIN2B 878/4885PNMT 127/4885ADRA2A 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.